Skip to main content

Simulations Plus, Bioreason, IBM, Ariadne, TEDCO, BioFortis, NHGRI, Velcura, GeneGo, HHS

Premium

Simulations Plus Acquires Bioreason for $788K

Simulations Plus said last week that it has acquired all assets of Santa Fe, NM-based cheminformatics firm Bioreason in an all-cash transaction for approximately $788,000.

Through the transaction, Simulations Plus acquired software, source code, two patents, trademarks, marketing and sales information, and all other fixed assets.

The purchase follows the company's acquisition of Sage Informatics in September [BioInform 09-12-05].

Simulations Plus said that Bioreason's flagship software, ClassPharmer will be integrated into a single product with Sage Informatics ChemTK package.

ClassPharmer is currently licensed to over 30 companies in the US, Europe, and Japan.

Momoko Beran, chief financial officer of Simulations Plus, said in a statement that Bioreason's assets include nearly $400,000 in accounts receivable from multi-year licenses, "with some of these due as early as this month. Most companies license on an annual basis, and if all licenses that will expire during this fiscal year are renewed, revenues from such licenses would exceed $500,000."


IBM Collaborates with Three Cancer Centers

IBM said last week that it is partnering with Memorial Sloan-Kettering Cancer Center, the Molecular Profiling Institute, and the CHU Sainte-Justine Research Center — Mother and Child University Hospital Center under separate agreements.

With MSKCC, IBM is building an integrated information management system to help clinicians and researchers study long-term cancer-related illnesses. IBM said it is providing a grant of technology and services worth $3 million to integrate MSKCC's hospital data with text-mining and other analytical capabilities "to facilitate predictive analysis and research." In addition, pathologists at MSKCC will work with researchers at IBM to create a searchable database for pathology reports.

In the Molecular Profiling Institute collaboration, IBM is building the IT infrastructure to support a software system under development at MPI that will send physicians and clinicians a tailored report based on a patient's complete molecular profile. MPI is the commercial arm of the Translational Genomics Research Institute.

At the CHU Sainte-Justine Research Center — Mother and Child University Hospital Center, a university teaching hospital affiliated with the University of Montreal, IBM is using its Clinical Genomics Solution platform as the basis of an informatics infrastructure to help define the genetic markers for acute lymphoblastic leukemia.

According to CHU, clinical data that was once manually extracted from hospital patient files will now be electronically transmitted and merged with genomic data to create a Medical Information Repository, which is expected to shorten a query process from days to minutes.


Ariadne Secures $75K from Maryland's TEDCO for Biosimulation Software Development

Ariadne Genomics said last week that the Maryland Technology Development Corporation (TEDCO) has provided $75,000 in early-stage funding to support the development of new biological pathway simulation software.

The company said in a statement that the new software, called PathwaySolver, "will emulate the dynamics of biological pathways by calculating concentrations of biochemical compounds for different times and conditions." Ariadne said the software will help researchers explore the effects of initial concentrations of particular cellular compounds or drug candidates on cellular behavior.

The company will integrate the pathway simulation module with its PathwayStudio and PathwayExpert products.


BioFortis Signs Software Contract with NHGRI

BioFortis of Baltimore, Md., said last week that it had secured a contract to provide the National Human Genome Research Institute with its web-based Labmatrix software, which integrates clinical data with genomic and laboratory data.

The contract covers unlimited use by all NHGRI intramural researchers and their collaborators, BioFortis said.

The deal is "a significant milestone for BioFortis, as it validates the efficacy and power of our software solution," said Jian Wang, BioFortis president and CEO, in a statement.

The company did not disclose financial terms of the agreement.


Velcura Licenses GeneGo's MetaCore

Velcura Therapeutics has licensed GeneGo's MetaCore pathway database and data-mining suite, GeneGo said last week.

All Velcura employees will have access to the MetaCore database and suite of software tools for three years, which they are using for bone-related disease research, GeneGo said.

Velcura Therapeutics is focused on developing drugs that stimulate bone formation. The company grows human bone outside the body and analyzes this process to develop novel therapies for osteoporosis and other bone diseases.


HHS Awards $18.M in Contracts for Health Information Network

The US Department of Health and Human Services has awarded four contracts totaling $18.6 million to develop prototypes for a Nationwide Health Information Network architecture.

The contracts were awarded to four consortia led by Accenture, Computer Sciences Corporation (CSC), IBM, and Northrop Grumman. Each consortium will develop an architecture and a prototype network for information sharing among hospitals, laboratories, pharmacies, and physicians. The design for each network will be placed in the public domain.

The contracts follow $39.8 million in grants that HHS awarded last month to groups developing interoperable electronic health records and implementing health information technology systems. [BioInform 10-10-05].

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.